
    
      Part A: Subjects will receive 2 doses of the vaccine, GBS-NN, and will be followed for 12
      weeks after the first dose of the vaccine. The following safety endpoints will be evaluated
      to support this objective: local and systemic reactogenicity; adverse events; laboratory
      tests; urinalysis; vital signs; 12-Lead ECG parameters; physical examination. In addition
      hereto, immunological parameters will be evaluated.

      Part B: Subjects will receive one or 2 doses of GBS-NN, and will be followed for 12 months
      after the first dose of the vaccine. The following safety endpoints will be evaluated to
      support this objective: local and systemic reactogenicity; adverse events; laboratory tests;
      urinalysis; vital signs; 12-Lead ECG parameters; physical examination. In addition hereto,
      immunological parameters will be evaluated.
    
  